Drugs / Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02336087 | Jan 2016 → Oct 2020 overdue | pancreatic adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02227940 | Jan 2015 → Dec 2018 | pancreatic adenocarcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02562716 | Jan 2016 → May 2020 | pancreatic adenocarcinoma | SWOG Cancer Research Network | Completed | Missed primary |
| Phase 2 | NCT01730833 | Jul 2013 → Jan 2021 | HER2 positive breast carcinoma, female breast carcinoma, inflammatory breast carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00618657 | Feb 2008 → Jul 2021 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer, female breast carcinoma | University of California, Irvine | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02620865 Background | Dec 2015 → Jun 2021 | pancreatic adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel Albumin-Stabilized Nanoparticle Formulation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02336087 ↗ |
| Route | Intravenous | “Given IV” NCT00618657 ↗ |